Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinicogenetic Risk-Stratified Management in Older AML
NCT03226418Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Jul 2017
- Primary completion
- Mar 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), myeloid sarcoma (MS), myelodysplastic syndrome (MDS), myeloid neoplasm, sponsored by University of Nebraska. Started Jul 2017; status: completed.
02
Drugs
venetoclaxdaunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)myeloid sarcoma (MS)myelodysplastic syndrome (MDS)myeloid neoplasm
Beyond the preview
Go deeper on NCT03226418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226418.